Exploring Connections Between Weight‐Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database

Endocrinology Diabetes & Metabolism, Journal Year: 2025, Volume and Issue: 8(2)

Published: March 1, 2025

ABSTRACT Aims GLP‐1 receptor agonists, such as semaglutide (Ozempic) and tirzepatide (Monjaro), have gained significant popularity for obesity management, but concerns arisen about their potential link to thyroid cancer. This study investigates the association between cancer weight‐loss medications. Materials Methods A disproportionality analysis was conducted using data from FDA Adverse Event Reporting System (FAERS) 2004 Q1 2024. odds ratios (RORs) were used identify associations drugs, including anti‐diabetic Results Significant positive with found agonists: (ROR = 7.61, 95% CI: 6.37–9.08), dulaglutide 3.59, 3.03–4.27), liraglutide 15.59, 13.94–17.44) 2.09, 1.51–2.89). weak inverse observed metformin 0.58, 0.36–0.93). No other topiramate, dapagliflozin insulin glargine. Conclusion The study, based on FAERS database, suggests a agonists an increased risk. These findings underscore importance of further research continuous safety monitoring when prescribing these medications management.

Language: Английский

---

Adverse drug reaction patterns of GLP‐1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: April 2, 2025

This study aims to compare adverse drug reaction patterns of liraglutide, semaglutide and tirzepatide-glucagon-like peptide-1 receptor agonists (GLP-1 RAs) approved for anti-obesity medications-to evaluate their real-world safety. disproportionality analysis utilized a case-control design with VigiBase. The focused on reports events associated tirzepatide, selected based warnings in the US Food Drug Administration approval labels each drug. Data were restructured using unique identifiers differentiate individuals affected by reactions. Multivariable logistic regression models estimated adjusted reporting odds ratios (aRORs) 95% confidence intervals (CIs) assess association between various GLP-1 RAs, adjusting age, sex, region, reporter qualification, year concomitant medication. information component (IC) was analysed, signals reactions considered significant only when both aROR IC statistically significant. Our targeted included 24 725 21 454 11 538 tirzepatide. Tirzepatide had fewer compared other two drugs, its pharmacovigilance strength lowest. Semaglutide, however, significantly several unusual events, including suicidal ideation behaviour (IC, 1.53 [IC025, 1.28]; aROR, 2.52 [95% CI, 2.18-2.93]), hair loss 0.78 0.63]; 1.42 1.30-1.55]) vision 1.27 1.13]; 1.80 1.66-1.97]). findings emphasize need cautious prescribing further research ensure safe use these medications.

Language: Английский

---

On the Frontlines of Cardiovascular-Kidney-Metabolic Syndrome: A Review of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Cardiovascular and Kidney Health

American Journal of Health-System Pharmacy, Journal Year: 2025, Volume and Issue: unknown

Published: April 8, 2025

Abstract Purpose The purpose of this review is to highlight the role glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) (GLP-1/GIP in managing cardiovascular-kidney-metabolic (CKM) syndrome, focusing on their cardiovascular (CV) kidney-protective effects beyond glycemic control. Summary In multiple randomized controlled trials, GLP-1 RAs were demonstrated confer significant benefits reducing CV events preserving kidney function patients with preexisting atherosclerotic disease (ASCVD) those at high risk. Current guidelines, including from Kidney Disease: Improving Global Outcomes (KDIGO) initiative American Diabetes Association (ADA), underscore therapeutic potential these agents for chronic (CKD), type 2 diabetes mellitus (T2DM), metabolic syndrome. Additionally, emerging data suggests utility T2DM. This summarizes evidence supporting along newer findings not yet fully integrated into clinical practice. It also examines pharmacists multidisciplinary teams, safety considerations, practical strategies common adverse effects. Conclusion integration GLP-1/GIP practice offers substantial patients, both without diabetes. Pharmacists play a pivotal recommending evidence-based treatments risk, educating addressing social determinants health, bridging gaps across care teams.

Language: Английский

---

Eine neue Ära der Diabetestherapie – Komorbiditäten im Fokus!

Gefässchirurgie, Journal Year: 2025, Volume and Issue: unknown

Published: April 28, 2025

---

RE：GLP-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data

JNCI Journal of the National Cancer Institute, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 10, 2024

Language: Английский

---